<div id="readability-page-1"><div><p>CSPC Innovation Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 1,593.01 million compared to CNY 1,478.92 million a year ago. Revenue was CNY 1,593.01 million compared to CNY 1,478.92 million a year ago.</p><p>Net loss was CNY 24.05 million compared to net income of CNY 139.33 million a year ago. Basic loss per share from continuing operations was CNY 0.0173 compared to basic earnings per share from continuing operations of CNY 0.0995 a year ago. Diluted loss per share from continuing operations was CNY 0.0173 compared to diluted earnings per share from continuing operations of CNY 0.0995 a year ago.</p></div></div>

新诺威

<p>新诺威制药有限公司报告了截至 2025 年 9 月 30 日的九个月财报。公司实现销售额为 15.9301 亿元人民币，较去年 14.7892 亿元人民币有所增长。然而，公司净亏损为 2405 万元人民币，较去年净利润 1.3933 亿元人民币大幅下降。持续经营业务的基本和摊薄每股亏损均为 0.0173 元人民币，而一年前每股收益为 0.0995 元人民币</p>

新诺威制药有限公司公布了截至2025年9月30日的九个月财务业绩